← Back to headlines
Guggenheim Raises Johnson & Johnson Target on Icotyde Upside
Guggenheim has increased its price target for Johnson & Johnson (JNJ) due to the potential upside from Icotyde, while maintaining a 'Buy' rating on the stock.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
